Odesivimab

Drug profile

Key facts

Odesivimab is a drug catalogued in DrugCentral. It was first approved by the FDA in 2020. DrugCentral lists 2 molecular targets, including FCGR3A and GP. Recorded indications include Ebola virus disease.

• Molecular targets: FCGR3A and GP (2 listed in DrugCentral).
• Indications: Ebola virus disease.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Ebola virus disease

Mechanism & targets

Molecular targets (2)

Target	Gene	Action	Activity
Low affinity immunoglobulin gamma Fc region receptor III-A	FCGR3A	other	EC50 8.80
Envelope glycoprotein	GP	other	Kd 8.08

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2020-10-14	FDA	—	REGENERON PHARMACEUTICALS	Yes

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Odesivimab used for?

DrugCentral lists the following indications for Odesivimab: Ebola virus disease.

How does Odesivimab work?

Its molecular targets in DrugCentral include FCGR3A and GP.

When was Odesivimab first approved?

Odesivimab was first approved by the FDA in 2020.

Sources

• DrugCentral drug card 5438 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4298188 — compound record and bioactivity
• DrugBank DB15900 — drug record
• FDA UNII UY9LQ8P6HW — substance identity
• DailyMed: FDA labels for Odesivimab — current prescribing information (label search)
• UniProt P08637 (FCGR3A) — target protein

How this page is built: methodology · editorial policy & corrections.